Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
224
View Count
10678
Example Insights
Report Description
Since the discovery of the means to artificially synthesize radioisotopes (early 1930s), they were almost immediately adopted for healthcare applications, by the mid-1940s. Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals. Despite their inherent toxicity, nuclear medicine is considered an important part of modern healthcare, with applications spanning across a number of therapeutic areas, including infectious diseases, immunological disorders, gastroenteric disease, cardiological disorders, oncological disorders, neurological disorders, and even certain psychiatric conditions. According to an article published by World Nuclear Association in May 2020, more than 10,000 hospitals worldwide claim to be using radioisotopes for various medical procedures; interestingly, of the aforementioned applications, 90% were reported to be related to disease diagnosis Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). It is worth highlighting that around 40 million diagnostic procedures, involving the use of the radioisotope Tc-99m alone, are conducted worldwide annually. Further, the introduction of the concept of theranostics, which involves the use of a single active ingredient for both diagnostic and therapeutic purposes, has opened up a new dimension of applications for nuclear medicine.
Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication. As a result, the demand for such specialized chemicals has grown at an exponential rate. However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise. Therefore, acquiring the necessary technical acumen and infrastructure to support such operations is not a feasible option for pharmaceutical companies, owing to a number of associated clauses and concerns (such as need for high capital investments, unique operating licenses and compliance to special regulatory requirements). Currently, stakeholders in the pharmaceutical industry primarily rely on suppliers and contract manufacturers to fulfill their radiopharmaceutical procurement needs. Moreover, there are a number of specialty service providers that claim to be engaged in this field, offering a variety of radioisotopes and affiliated services for healthcare applications. As more applications are discovered, the demand for nuclear material suppliers and service providers is likely to increase. This, coupled to the anticipated advances in the field of radiopharmaceuticals, affiliated technologies and products, is expected to offer lucrative opportunities to the contract service providers that are engaged in this domain.
The ‘Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030’ report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:
One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the radiopharmaceutical manufacturing market, over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (cardiology, neurology, oncology, thyroid and others), [B] application area (diagnostic and therapeutic) and [C] type of diagnostic radiopharmaceuticals (PET and SPECT), [D] type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), [E] purpose of production (in-house / outsourcing) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (arranged in the order of participant’s designation):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of nuclear medicine and radiopharmaceutical manufacturing market, in the short to mid and long term.
Chapter 3 provides a general introduction and a brief historical background of nuclear medicines and radiopharmaceuticals. It includes details on the applications of radiopharmaceuticals in the medical field, as well as various methods adopted by manufacturers for the production of radiopharmaceuticals. It also highlights the guidelines laid down by regulatory authorities for the production, packaging, labelling and storage, of radiopharmaceuticals. In addition, it features a discussion on the need for outsourcing in this field. Further, it presents the key requisites for the selection of a CMO partner and key future perspectives related to the use of radiopharmaceuticals within the nuclear medicine industry.
Chapter 4 provides a detailed overview of around 60 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of radiopharmaceuticals. The chapter provides details on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
Chapter 5 provides an overview of around 70 non-industry players (academia and research institutes) that are actively involved in the production of radiopharmaceuticals. The chapter provides details on the year of establishment, purpose of production (fulfilling in-house requirements / for contract services), location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT) and type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others).
Chapter 6 features tabulated profiles of the mid-large sized US based contract service providers / in-house manufacturers that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook..
Chapter 7 features tabulated profiles of the large EU based contract service providers / in-house manufacturers that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook.
Chapter 8 features tabulated profiles of the mid-large sized contract service providers / in-house manufacturers based in Asia-Pacific and rest of the world, that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook.
Chapter 9 features a four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, the scale at which they manufacture their respective products and company size.
Chapter 10 features an analysis of recent partnerships and collaborations inked in this domain, since 2017. It includes a brief description of the partnership models (including manufacturing / supply agreement, acquisition / merger, product development agreement and commercialization agreement, R&D agreement, licensing agreement, asset acquisition, distribution agreement, clinical trial agreement, process development agreement and others) that have been adopted by the stakeholders in this domain. It also includes the analysis based on various parameters such as year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement and application of the radioisotope mentioned in the agreement. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 11 presents a detailed discussion on the supply chain model of medical isotope Mo-99 / Tc-99m, highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.
Chapter 12 presents an informed estimate of the current and future opportunity in the nuclear medicine and radiopharmaceutical manufacturing market, highlighting the likely growth of the market till the year 2030. The chapter presents a detailed market segmentation on the basis of target therapeutic area (cardiology, nephrology, oncology, thyroid and others), application area (diagnostic and therapeutic), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), purpose of production (in-house / outsourcing) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world).
Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (arranged in the order of participant’s designation) James Davis (Vice President Quality / R&D, Shertech Laboratories), Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina Medical School), Jan Pruim (Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen), Michael van Dam (Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology) and Anonymous (ITM Isotopen Technologien München).
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Nuclear Medicines and Radiopharmaceuticals
3.3. Historical Evolution of Radiopharmaceuticals
3.4. Applications of Radiopharmaceuticals
3.4.1. Nuclear Imaging / Diagnosis
3.4.1.1. Single Photon Emission Computed Tomography
3.4.1.2. Positron Emission Tomography
3.4.2. Therapeutic Use
3.5. Production of Radiopharmaceuticals
3.5.1. Radionuclide Generator
3.5.2. Particle Accelerator (Cyclotron)
3.5.3. Nuclear Reactor
3.6. Regulatory Framework for Radiopharmaceuticals
3.6.1. Guidelines for the Production of Radiopharmaceuticals
3.6.2. Guidelines for Labelling and Packaging of Radiopharmaceuticals
3.6.3. Guidelines for Storage of Radiopharmaceuticals
3.7. Need for Outsourcing Radiopharmaceuticals Manufacturing
3.8. Selecting a CMO Partner for Radiopharmaceuticals Manufacturing
3.9. Current Scenario and Future Prospects Related to Radiopharmaceuticals
4. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Production
4.2.4. Analysis by Geographical Location of Headquarters
4.2.5. Analysis by Geographical Location of Manufacturing Facilities
4.2.6. Analysis by Scale of Production
4.2.7. Analysis by Application Area
4.2.8. Analysis by Type of Radioisotope
4.2.8.1. Radioisotopes for Diagnostic Use
4.2.8.2. Radioisotopes for Therapeutic Use
4.2.9 Analysis by Target Therapeutic Area
4.2.10 Analysis by Service(s) Offered
5. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (NON-INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Purpose of Production
5.2.3. Analysis by Geographical Location of Manufacturing Facilities
5.2.4. Analysis by Scale of Production
5.2.5. Analysis by Application Area
5.2.6. Analysis by Type of Radioisotopes
5.2.6.1. Radioisotopes for Diagnostic Use
5.2.6.2. Radioisotopes for Therapeutic Use
6. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Cardinal Health
6.2.1. Company Overview
6.2.2. List of Products and Manufacturing Facilities
6.2.3. Recent Developments and Future Outlook
6.3. GE Healthcare
6.3.1. Company Overview
6.3.2. List of Products and Manufacturing Facilities
6.3.3. Recent Developments and Future Outlook
6.4. Jubilant Radiopharma
6.4.1. Company Overview
6.4.2. List of Products and Manufacturing Facilities
6.4.3. Recent Developments and Future Outlook
6.5. Lantheus Medical Imaging
6.5.1. Company Overview
6.5.2. List of Products and Manufacturing Facilities
6.5.3. Recent Developments and Future Outlook
6.6. Nordion
6.6.1. Company Overview
6.6.2. List of Products and Manufacturing Facilities
6.6.3. Recent Developments and Future Outlook
6.7. SOFIE
6.7.1. Company Overview
6.7.2. List of Products and Manufacturing Facilities
6.7.3. Recent Developments and Future Outlook
7. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN EUROPE
7.1. Chapter Overview
7.2. Advanced Accelerator Applications
7.2.1. Company Overview
7.2.2. List of Products and Manufacturing Facilities
7.2.3. Recent Developments and Future Outlook
7.3. SCK•CEN
7.3.1. Company Overview
7.3.2. List of Products and Manufacturing Facilities
7.3.3. Recent Developments and Future Outlook
7.4. Curium Pharma
7.4.1. Company Overview
7.4.2. List of Products and Manufacturing Facilities
7.4.3. Recent Developments and Future Outlook
7.5. Eckert & Ziegler
7.5.1. Company Overview
7.5.2. List of Products and Manufacturing Facilities
7.5.3. Recent Developments and Future Outlook
7.6. PETNET Solutions
7.6.1. Company Overview
7.6.2. List of Products and Manufacturing Facilities
7.6.3. Recent Developments and Future Outlook
8. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN ASIA-PACFIC AND REST OF THE WORLD
8.1. Chapter Overview
8.2. China Isotope & Radiation Corporation
8.2.1. Company Overview
8.2.2. List of Products and Manufacturing Facilities
8.2.3. Recent Developments and Future Outlook
8.3. DuChemBio
8.3.1. Company Overview
8.3.2. List of Products and Manufacturing Facilities
8.3.3. Recent Developments and Future Outlook
8.4. Eczacibasi-Monrol
8.4.1. Company Overview
8.4.2. List of Products and Manufacturing Facilities
8.4.3. Recent Developments and Future Outlook
8.5. Nihon Medi-Physics
8.5.1. Company Overview
8.5.2. List of Products and Manufacturing Facilities
8.5.3. Recent Developments and Future Outlook
8.6. Sinotau Pharmaceuticals
8.6.1. Company Overview
8.6.2. List of Products and Manufacturing Facilities
8.6.3. Recent Developments and Future Outlook
9. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Assumptions and Key Parameters
9.4. Four-Dimensional Bubble Analysis based on Supplier Power, Product Portfolio Strength and Manufacturing Capabilities
9.4.1. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
9.4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
9.4.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Type of Partnership
10.3.2. Analysis by Year of Partnership
10.3.3. Analysis by Type of Radioisotope
10.3.4. Analysis by Target Therapeutic Area Mentioned in the Agreement
10.3.5. Analysis by Application Mentioned in the Agreement
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.8. Intercontinental and Intracontinental Agreements
11. PRODUCTION AND SUPPLY CHAIN OF MEDICAL ISOTOPE MOLYBDENUM-99 (TECHNETIUM-99M)
11.1. Chapter Overview
11.2. Production and Use of Mo-99
11.2.1. Reactor-based Production
11.2.2. Accelerator-based Production
11.3. Supply Chain of Mo-99
11.3.1. Target Suppliers
11.3.2. Irradiation Service Providers
11.3.3. Mo-99 Suppliers
11.3.4. Technetium Generator Suppliers
11.3.5. Tc-99m End-Users
11.4. Future Prospects
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030
12.3.1. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area
12.3.2. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area
12.3.3. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals
12.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals
12.3.5. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production
12.3.6. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions
13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Shertech Laboratories
14.2.1. Company Snapshot
14.2.2. Interview Transcript: James Davis, Vice President Quality / R&D
14.3. University of Ioannina
14.3.1. Organization Snapshot
14.3.2. Interview Transcript: Andreas Fotopoulos, Professor of Nuclear Medicine
14.4. University Medical Center Groningen
14.4.1. Organization Snapshot
14.4.2. Interview Transcript: Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician
14.5. Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
14.5.1. Organization Snapshot
14.5.2. Interview Transcript: Michael van Dam, Professor
14.6. ITM Isotopen Technologien München
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Anonymous
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
Figure 3.1 Structure of a Radiopharmaceuticals Product
Figure 3.2 Production of Radiopharmaceuticals: Radionuclide Generator
Figure 3.3 Production of Radiopharmaceuticals: Particle Accelerator (Cyclotron)
Figure 3.4 Production of Radiopharmaceuticals: Nuclear Reactor
Figure 3.5 Geographical Distribution of Regulatory Bodies Governing the Production of Radiopharmaceuticals
Figure 3.6 Selecting a CMO Partner for Radiopharmaceuticals Production: Parameters to Consider
Figure 4.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Cumulative Distribution by Year of Establishment
Figure 4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Purpose of Production
Figure 4.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Figure 4.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Geographical Location of Headquarters
Figure 4.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
Figure 4.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Scale of Production
Figure 4.9 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Scale of Production
Figure 4.10 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Application Area
Figure 4.11 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Diagnostic Radioisotopes
Figure 4.12 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Therapeutic Radioisotopes
Figure 4.13 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Target Therapeutic Area
Figure 4.14 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Service(s) Offered
Figure 5.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Cumulative Distribution by Year of Establishment
Figure 5.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Purpose of Production
Figure 5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continent-wise)
Figure 5.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Country-wise)
Figure 5.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Scale of Production
Figure 5.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 5.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radioisotopes
Figure 5.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radioisotopes
Figure 9.1 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
Figure 9.2 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
Figure 9.3 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World
Figure 10.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2017-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Radioisotope
Figure 10.4 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Figure 10.5 Partnerships and Collaborations: Distribution by Application Mentioned in the Agreement
Figure 10.3 Most Active Players: Distribution by Number of Partnerships
Figure 10.4 Partnerships and Collaborations: Geographical Distribution
Figure 10.5 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.2 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area (USD Billion)
Figure 12.3 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area (USD Billion)
Figure 12.4 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals (USD Billion)
Figure 12.5 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals (USD Billion)
Figure 12.6 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production (USD Million)
Figure 12.7 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Table 3.1 List of Commonly Used SPECT Radionuclides
Table 3.2 List of Commonly Used PET Radionuclides
Table 3.3 List of Commonly Used Radionuclides for Therapeutic Applications
Table 3.4 List of Generator, Particle Accelerator (Cyclotron) and Reactor Produced Radionuclides
Table 3.5 List of FDA Approved Radiopharmaceuticals
Table 4.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Industry Players
Table 4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Location of Manufacturing Facilities and Scale of Production
Table 4.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Application Area
Table 4.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Diagnostic Radioisotopes
Table 4.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Therapeutic Radioisotopes
Table 4.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Target Therapeutic Area
Table 4.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Service(s) Offered
Table 5.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Non-Industry Players
Table 5.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Scale of Production
Table 5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Application Area
Table 5.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Diagnostic Radioisotopes
Table 5.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Therapeutic Radioisotopes
Table 6.1 Cardinal Health: Company Snapshot
Table 6.2 Cardinal Health: Products and Manufacturing Facilities
Table 6.3 Cardinal Health: Recent Developments and Future Outlook
Table 6.4 GE Healthcare: Company Snapshot
Table 6.5 GE Healthcare: Products and Manufacturing Facilities
Table 6.6 GE Healthcare: Recent Developments and Future Outlook
Table 6.7 Jubilant Radiopharma: Company Snapshot
Table 6.8 Jubilant Radiopharma: Products and Manufacturing Facilities
Table 6.9 Jubilant Radiopharma: Recent Developments and Future Outlook
Table 6.10 Lantheus Medical Imaging: Company Snapshot
Table 6.11 Lantheus Medical Imaging: Products and Manufacturing Facilities
Table 6.12 Lantheus Medical Imaging: Recent Developments and Future Outlook
Table 6.13 Nordion: Company Snapshot
Table 6.14 Nordion: Products and Manufacturing Facilities
Table 6.15 Nordion: Recent Developments and Future Outlook
Table 6.16 SOFIE: Company Snapshot
Table 6.17 SOFIE: Products and Manufacturing Facilities
Table 6.18 SOFIE: Recent Developments and Future Outlook
Table 7.1 Advanced Accelerator Applications: Company Snapshot
Table 7.2 Advanced Accelerator Applications: Products and Manufacturing Facilities
Table 7.3 Advanced Accelerator Applications: Recent Developments and Future Outlook
Table 7.4 SCK•CEN: Company Snapshot
Table 7.5 SCK•CEN: Products and Manufacturing Facilities
Table 7.6 SCK•CEN: Recent Developments and Future Outlook
Table 7.7 Curium Pharma: Company Snapshot
Table 7.8 Curium Pharma: Products and Manufacturing Facilities
Table 7.9 Curium Pharma: Recent Developments and Future Outlook
Table 7.10 Eckert & Ziegler: Company Snapshot
Table 7.11 Eckert & Ziegler: Products and Manufacturing Facilities
Table 7.12 Eckert & Ziegler: Recent Developments and Future Outlook
Table 7.13 PETNET Solutions: Company Snapshot
Table 7.14 PETNET Solutions: Products and Manufacturing Facilities
Table 7.15 PETNET Solutions: Recent Developments and Future Outlook
Table 8.1 China Isotope & Radiation Corporation: Company Snapshot
Table 8.2 China Isotope & Radiation Corporation: Products and Manufacturing Facilities
Table 8.3 China Isotope & Radiation Corporation: Recent Developments and Future Outlook
Table 8.4 DuChemBio: Company Snapshot
Table 8.5 DuChemBio: Products and Manufacturing Facilities
Table 8.6 DuChemBio: Recent Developments and Future Outlook
Table 8.7 Eczacibasi-Monrol: Company Snapshot
Table 8.8 Eczacibasi-Monrol: Products and Manufacturing Facilities
Table 8.9 Eczacibasi-Monrol: Recent Developments and Future Outlook
Table 8.10 Nihon Medi-Physics: Company Snapshot
Table 8.11 Nihon Medi-Physics: Products and Manufacturing Facilities
Table 8.12 Nihon Medi-Physics: Recent Developments and Future Outlook
Table 8.13 Sinotau Pharmaceuticals: Company Snapshot
Table 8.14 Sinotau Pharmaceuticals: Products and Manufacturing Facilities
Table 8.15 Sinotau Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1 Nuclear Medicines and Radiopharmaceuticals Manufacturing: List of Partnerships and Collaborations
Table 15.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Cumulative Distribution by Year of Establishment
Table 15.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players) Distribution by Company Size
Table 15.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Purpose of Production
Table 15.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Table 15.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Table 15.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Geographical Location of Headquarters
Table 15.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
Table 15.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Scale of Production
Table 15.9 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Scale of Production
Table 15.10 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Application Area
Table 15.11 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Diagnostic Radioisotopes
Table 15.12 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Therapeutic Radioisotopes
Table 15.13 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Target Therapeutic Area
Table 15.14 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Service(s) Offered
Table 15.15 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Cumulative Distribution by Year of Establishment
Table 15.16 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Purpose of Production
Table 15.17 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continent-wise)
Table 15.18 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Country-wise)
Table 15.19 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Scale of Production
Table 15.20 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Application Area
Table 15.21 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radioisotopes
Table 15.22 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radioisotopes
Table 15.23 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2017-2020
Table 15.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.25 Partnerships and Collaborations: Distribution by Type of Radioisotope
Table 15.26 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Table 15.27 Partnerships and Collaborations: Distribution by Application Area
Table 15.28 Most Active Players: Distribution by Number of Partnerships
Table 15.29 Partnerships and Collaborations: Geographical Distribution
Table 15.30 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.31 Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.32 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Target Therapeutic Area (USD Billion)
Table 15.33 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Application Area (USD Billion)
Table 15.34 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals (USD Billion)
Table 15.35 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals (USD Billion)
Table 15.36 Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Purpose of Production (USD Million)
Table 15.37 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Key Geographical Regions (USD Million)
The following companies and organizations have been mentioned in the report.